Document:

EX-10.9

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  Page
 1
 of 6 
  

 Exhibit 10.9 

MATERIAL TRANSFER AND CONFIDENTIALITY AGREEMENT 

This Material and Confidentiality Agreement (“Agreement”) is by and between: 

Crucell Holland B.V., a dutch Company with offices located at Archimedesweg 4, 2333 CN, Leiden, the Netherlands, hereinafter referred to as
“CRUCELL”; and 
 Vascular Biogenics Ltd., with offices located at 6 Jonathan Netanyahu Street, 60376, Or-Yehuda, Israel (hereinafter
referred to as “Vascular Biogenics”; and 
 BioReliance Ltd., a company with offices located at Innovation Park, Hillfoots Road, Stirling
FK9 4NF, hereinafter referred to as “Contractor”. 
 (hereinafter individually referred to as “Party” and collectively as
“Parties”) 
 WHEREAS CRUCELL is the owner of a proprietary PER.C6® cell line
(hereinafter referred to as “MATERIAL”), and of related proprietary and confidential information and patent rights; 
 WHEREAS CRUCELL and
Vascular Biogenics have signed a research license and option agreement for the conduct of research & development programs that employ PER.C6® cells to manufacture, use and develop a
pharmaceutical products in the gene therapy field, effective as of March 24 2000 (“License”); 
 WHEREAS under Vascular Biogenics’
rights under Section 2.1.4 of the License, Vascular Biogenics wishes Contractor to perform certain scientific work within the field described in Attachment I, hereinafter referred to as the “Statement of Work”, using the MATERIAL and
related proprietary and confidential information (“INFORMATION”) (MATERIAL and INFORMATION hereinafter collectively referred to as “Know How”) on the condition that Contractor enter Into this Agreement with Vascular Biogenics and
Crucell; 
 WHEREAS Crucell is willing to make available the Know How to Contractor for the performance of the Statement of Work on behalf of Vascular
Biogenics; 
 WHEREAS the Parties wish to make arrangements with respect to the use by Contractor of the MATERIAL, and of the results of the Statement of
Work Performed thereon. 
 NOW, THEREFORE, the Parties hereto, intending to be legally bound, agree as follows: 

 

	 	1.	Supply of Know How: Crucell agrees to provide and consents to Vascular Biogencs’s providing, the MATERIAL and the INFORMATION to Contractor upon the execution of this Agreement; solely for scientific use
under the Statement of Work, If Crucell is requested to deliver MATERIAL and INFORMATION to Contractor, Crucell shall ship the MATERIAL and the INFORMATION to Contractor at Vascular Biogenics expense. 

 

	 	2.	Permitted and Restricted Uses: Contractor shall only use the MATERIAL: 

  

	 	2.1.	for scientific research solely in the performance of the statement of Work and solely in its own laboratories. 

  

	 	2.2.	solely for the purpose of the Statement of Work; 

 and not use the MATERIAL: 

 

	 	2.3.	for administering MATERIAL, or any materials produced therefrom, to humans; 

  

	 	2.4.	for purposes of commercial production or sale; 

  
 Portions of this
exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  Page
 2
 of 6 
  

	 	2.5.	with any other entity or organization other than Vascular Biogenics. 

  

	 	2.6.	to chemically or biologically modify MATERIAL, except as contemplated by this Agreement in accordance with the explicit purpose of the Statement of Work, unless otherwise agreed to in writing by Crucell.

  

	 	2.7.	to modify, alter, change and/or reconstruct the MATERIAL, other than as further described in the Statement of Work in Attachment I. 

  

	 	3.	Ownership of results and materials: Subject to the terms and conditions agreed between Vascular Biogenics and Crucell in the License, all rights to any materials, data and any physical, chemical, or biological
results (hereinafter referred to collectively as “RESULTS”) generated under the Statement of Work will vest in Vascular Biogenics. If during the course and performance of the Statement of Work, one or more employees of Contractor conceive
or reduce to practice one or more inventions directly resulting from the Statement of Work, Contractor agrees that all right, title and interest in and to all such inventions, shall vest in Vascular Biogenics. For the avoidance of doubt, any
RESULTS, including inventions and patent applications and patents emanating therefrom shall constitute IMPROVEMENT KNOW HOW RIGHTS and/or IMPROVEMENT PATENT RIGHTS as defined in the license and consequently shall be subject to the grant-back
provision clause 2.3 of the License. Contractor shall promptly disclose such inventions to Vascular Biogenics, and at Vascular Biogenics’s cost and expense, including without limitation compensation for time expended by Contractor, shall
diligently cooperate with Vascular Biogenics in the preparation of patent applications covering such Inventions, prosecution of such applications and any other acts necessary for the protection of rights to such inventions, Including but no limited
to the execution of documents such as declarations and assignments to perfect Vascular Biogencis’s rights in and to such inventions, Contractor will refrain from any and all acts that may jeopardize the patentability of the invention in any
jurisdiction. 

 Notwithstanding the foregoing the Parties agree and acknowledge that all methodological innovations solely
related to Contractor’s assays, methods and technology and all know-how developed by Contractor solely related to Contractor’s assays, methods and technology arising as a result of work performed for Vascular Biogenics whether using the
Materials or otherwise shall remain the property of Contractor and no rights to same shall pass to Vascular Biogenics or Crucell in terms of this Agreement or otherwise. 
  

	 	4.	Contractor Control and Legal Obligations: Contractor shall at all times maintain control over the MATERIAL and comply with all applicable laws, regulations and guidelines related to the MATERIAL (hereinafter
collectively referred to as “the Rules”). Contractor will not, unless Crucell will have given prior written approval on conditions it deems fit, release, transfer or distribute the MATERIAL to any party other than Vascular Biogenics and
its authorized employees. 

  

	 	5.	Reporting: All RESULTS obtained from the screening, testing or use of MATERIAL by Contractor will be reported, under the confidentiality terms of Section 7, to Vascular Biogenics without delay.

  

	 	6.	 Termination: After the termination or expiration of this Agreement, Contractor shall transfer to Vascular Biogenics all remaining MATERIAL,
derivates and any substances obtained from the Statement of Work and confirm such in writing to the other Parties, or shall –at the request of Vascular Biogenics – diligently destroy the MATERIAL, derivatives and any substances derived

  
 Portions of this
exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  Page
 3
 of 6 
  

	 	
there from in accordance with the Rules referred to in Section 4, and confirm such in writing to the other Parties. Upon completion of review of Crucell’s INFORMATION by Contractor,
upon the request of Crucell or in the absence of further agreement between Vascular Biogenics all the provided INFORMATION, and any copies thereof in Its possession, promptly by registered mail, certified mail, or courier service, for example.
Federal Express, which retains record of the mailing, except that Contractor may retain one copy of such INFORMATION for the sole purpose of determining any continuing legal obligations to Crucell and Vascular Biogenics. 

 

	 	7.	Confidentiality Obligations: 

  

	 	7.1.	Contractor shall treat all RESULTS and INFORMATION as confidential and shall not itself use, except for the purposes of this Agreement, or disclose to any fourth party any of such RESULTS and INFORMATION, except as to
any of such RESULTS and INFORMATION which Contractor can establish: 

  

	 	(a)	at the time of disclosure is in the public domain; 

  

	 	(b)	after disclosure becomes part of the public domain by publication or, except by breach of this Agreement by Contractor or breach by any other party under an agreement of confidentiality to Crucell or Vascular Biogenics;

  

	 	(c)	by written records was in its possessions at the time of disclosure by Crucell or Vascular Biogenics and was not acquired directly or indirectly from Crucell, Vascular Biogenics or from any other party under an
agreement of confidentiality to Crucell or Vascular Biogenics; 

  

	 	(d)	Contractor receives from a fourth party legally in a position to provide Contractor with the INFORMATION or RESULTS, provided, however, that such was not obtained by said fourth party directly or indirectly from Crucell
or Vascular Biogenics under an obligation of secrecy; 

  

	 	(e)	is excepted by prior written approval of Crucell in the case of INFORMATION or RESULTS in the case of Vascular Biogenics; 

  

	 	(f)	is required by law to be disclosed; or 

  

	 	(g)	is Independently developed by Contractor without reference to the INFORMATION or RESULTS as evidence by records, however maintained. 

 

	 	7.2.	Contractor shall have the right to disclose RESULTS and INFORMATION to those directors, officers, employees and consultants of Contractor to whom such disclosure is necessary for the aforesaid purposes; provided that
those persons to whom such RESULTS and INFORMATION may be disclosed under this paragraph have undertaken in writing confidentiality obligations with respect to such RESULTS and INFORMATION substantially similar to those undertaken by Contractor
under this Agreement. 

  

	 	7.3.	 Contractor will take all reasonable steps, including but not limited to those steps taken to protect information, data or other tangible or Intangible
property of its own that it regards as proprietary or confidential, to ensure that the RESULTS and INFORMATION are not 

  
 Portions of this
exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  Page
 4
 of 6 
  

	 	
disclosed or duplicated for any unauthorized party’s use and to prevent the directors, officers, employees and consultants of Contractor from violating this Agreement. Contractor shall
notify Crucell and Vascular Biogenics promptly of its knowledge of any unauthorized use or unauthorized disclosure of RESULTS or INFORMATION. 

  

	 	8.	Title and all rights to all Crucell’s Know How disclosed under this Agreement remain vested in Crucell. 

  

	 	9.	Nothing in this Agreement is to be construed as a license to Contractor to utilize Crucell’s Know How, Trademarks, or trade names, except as provided in this Agreement, in any way whatsoever or under any patent or
patent application owned by Crucell, unless a separate written license agreement is executed. Any modification to this Agreement shall be in writing. 

  

	 	10.	Use of Names: None of the parties will use the name of another party hereto in relation to this Agreement in any advertising or other form of publicity, without the prior written approval of such party.

  

	 	11.	Limited Warranty: 

  

	 	11.1.	Vascular Biodenics and Crucell warrant that they own, possess, have access to, or are licensed under all patents, patent applications, inventions, improvements, trademarks, trade names, copyrights, licenses,
information, proprietary rights, processes, know-how necessary to permit BioRellance’s use of the Materials and Information for the purpose of the Statement of Work. 

 

	 	11.2.	Contractor acknowledges that the MATERIAL is experimental in nature and is being made available by Crucell and Vascular Biogenics for research purposes. Except as otherwise provided herein, Crucell and Vascular
Biogenics make no representation with regard to purity or biological activity of MATERIAL provided, MATERIAL is supplied “as is” with no warranties, express or implied, including any warranty of merchantability or fitness for a particular
purpose. 

  

	 	12.	Indemnification: Crucell shall not be liable for any claim or damage arising from or in connection with Contractor’s use, handling or storage of MATERIAL and Contractor and Vascular Biogenics shall hold
harmless and Indemnify Crucell for any such claim or damage, unless such claim or damage arises for any claim or damage arising from Vascular Biogenics’ use of RESULTS, and Vascular Biogenics shall hold harmless and indemnify Contractor for any
such claim or damage, unless such claim or damage arises from the negligence or wrong doing of Vascular Biogenics. 

  

	 	13.	Each party warrants that it is permitted to enter into this Agreement and that the terms of this Agreement are not inconsistent with other contractual obligations it may have. 

 

	 	14.	Notwithstanding the terms of this Agreement, no party to this Agreement shall be obligated to enter into any further agreement with the other. 

 

	 	15.	This Agreement is binding upon the parties hereto and their successors in business, but is not otherwise assignable, other than in connection with a merger, consolidation or sale of all or substantially all assets
related to the subject matter of this agreement. 

  

	 	16.	Effective Date, Termination Date and Survival: This Agreement will be effective on 19th September 2005 and will terminate after the earlier of
(i) the completion of the Statement of Work described in Attachment I, or (ii) twelve (12) months after the effective date. Section 3, 5, 6, 7, 11, 12, 14, 16, 18, 19 and 20 will survive any termination of this Agreement.

  
 Portions of this
exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  Page
 5
 of 6 
  

	 	17.	Except as otherwise set forth herein, this Agreement may not be modified, assigned or transferred in whole or in part by Contractor, unless Crucell will have given prior written approval on conditions it reasonably
deems fit. 

  

	 	18.	Contractor agrees that its obligations set forth in Sections 2, 4 and 7 are necessary and reasonable to protect Crucell and expressly agrees that monetary damages may be inadequate to compensate Crucell for any breach
of any covenant or agreement set forth in Sections 2, 4 or 7. Contractor agrees and acknowledges that any such violation or threatened violation may cause irreparable injury to Crucell and that in addition to any other remedies to seek injunctive
relief against any threatened breach of this Agreement or the continuation of any such breach, without the necessity of proving actual damages. 

  

	 	19.	This Agreement shall be exclusively governed by and construed in accordance with the laws of the Netherlands. All disputes arising out of or in relation to this agreement shall, to the exclusion of all others, be
referred exclusively to the competent Dutch Courts, and the Parties agree that judgments of the Parties. In the event of a dispute between the parties regarding this agreement, the parties shall first attempt to resolve their dispute through
amicable discussion. 

  

	 	20.	In case of conflict between the License and this Agreement, the provisions of the License shall prevail, except with respect to Contractor in which case this Agreement shall prevail. 

IN WITNESS WHEREOF, Contractor, Vascular Biogenics and Crucell have executed this Agreement by their respective, duly authorized,
representatives of the date hereinafter written: 
  

									
	CRUCELL HOLLAND B.V.	 		 	Vascular Biogenics Ltd.
	For and on behalf of Crucell N.V.	 		 	
					
	By:	 	/s/ Ronald H.P. Brus	 		 	By:	 	/s/ Elalouf Emmanuel
	Name:	 	Ronald H.P. Brus	 		 	Name:	 	Elalouf Emmanuel
	Function:	 	 President & CEO
	 		 	Function:	 	VP Business Development
		 	Leiden, October 3, 2005	 		 		 	Gaithersburg, September 20, 2005

  

			
	BioReliance Ltd.
		
	By:	 	/s/ Diana Mrogan
	Name:	 	Diana Morgan
	Function:	 	Global Leader Manufacturing
		 	Glasgow, September 19, 2005

  
 Portions of this
exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  Page
 6
 of 6 
  

 [***] 

  
 Portions of this
exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].EX-10.10

 Exhibit 10.10 

GENERAL SERVICES AGREEMENT 

BioClinica Agreement #40801 
 This General
Services Agreement (this “Agreement”) effective as of the last date of signature hereof (the “Effective Date”), by and between BioClinica, Inc., a Delaware Corporation, with its principal place of business at 826 Newtown-Yardley
Road, Newtown, Pennsylvania, 18940-1721 (“BIOCLINICA”) and Vascular Biogenics Ltd. with its principal place of business at 6 Jonathan Netanyahu Street, Or Yehuda, Israel 60376 (“VASCULAR BIOGENICS”). BIOCLINICA and VASCULAR
BIOGENICS are individually referred to as a “Party” and collectively as the “Parties”. 
 PURPOSE 

WHEREAS, BIOCLINICA has certain experience, knowledge and abilities that VASCULAR BIOGENICS wishes to utilize in developing and expanding various business and
organizational considerations, policy formations and overall strategic planning. 
 WHEREAS, VASCULAR BIOGENICS is in the trade or business of the
manufacture and sale of pharmaceutical, diagnostic and other scientific materials. 
 WHEREAS, BIOCLINICA is willing to provide consulting services to
VASCULAR BIOGENICS and desires to accept the arrangement upon the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual
promises and covenants contained herein, the Parties agree as follows: 
  

	1.	SCOPE OF SERVICES 

  

	 	1.1	BIOCLINICA will provide medical imaging core laboratory services to VASCULAR BIOGENICS as more fully set forth in the attached Exhibit A, which is hereby made part of this Agreement as if fully included herein (the
“Services”). Any special or related service which the Parties agree are outside the scope of the Services to be provided hereunder shall be covered under a separate agreement. 

 

	 	1.2	In providing Services under this Agreement, BIOCLINICA shall report to the VASCULAR BIOGENICS employee designated by VASCULAR BIOGENICS. 

 

	 	1.3	BIOCLINICA shall use commercially reasonable efforts and such working time as may be required for the satisfactory performance of the Services in accordance with this Agreement and shall comply with all applicable laws
and regulations in the performance of the Services. 

  

	 	1.4	BIOCLINICA shall perform the Services at BIOCLINICA facilities, such locations set forth on Exhibit A, or other such locations as are mutually agreed by the Parties. 

  
 1 

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

	 	1.5	BIOCLINICA represent and warrants that the execution and delivery of this Agreement and the fulfillment of the terms hereof will constitute the valid, binding and enforceable obligations of BIOCLINICA and will not
constitute a default under or breach of any agreement and/or undertaking and/or other instrument to which BIOCLINICA is a party or by which it is bound, or any provision of law, rule or regulation applicable to BIOCLINICA, including without
limitation, any confidentiality agreement; and in the performance of its obligations hereunder, BIOCLINICA will not make use of (i) any confidential or proprietary information belonging to any third party, or (ii) any information to which
BIOCLINICA is restricted from disclosing or using due to contractual undertakings (or by law). 

  

	2.	COMPENSATION 

  

	 	2.1	VASCULAR BIOGENICS agrees to pay as a fee to BIOCLINICA, for the Services rendered during the project, the amount and at such times as indicated in Exhibit A. 

 

	 	2.2	In addition to the fee specified in Exhibit A, VASCULAR BIOGENICS will reimburse BIOCLINICA for reasonable travel and out-of-pocket expenses related to the provision of the Services, provided that such expenses have
been pre-approved by VASCULAR BIOGENICS. Invoices for the Services and out-of-pocket expenses will be detailed according to tasks completed and will include all relevant backup documentation. A 0.5% per month carrying charge will be billed for
any undisputed fees and expenses not paid within thirty (30) days of invoice receipt. 

  

	 	2.3	In order to allow payments, BIOCLINICA will provide to VASCULAR BIOGENICS upon the execution of this Agreement a Certificate of Residency from its Tax Authorities (form 6166). 

 

	3.	INTELLECTUAL PROPERTY 

 BIOCLINICA agrees that any data, reports, materials, work product
or other deliverables generated as a result of the performance of the services, or that are derived from the use or possession of VASCULAR BIOGENICS’ confidential information (collectively, the “Data”) shall be the sole and exclusive
property of VASCULAR BIOGENICS. BIOCLINICA hereby assigns to VASCULAR BIOGENICS all right, title and interest to such Data, and all worldwide intellectual property rights therein, including without limitation, patents, copyrights, and trade secrets
(“VASCULAR BIOGENICS’ Intellectual Property Rights”). It is recognized and understood that certain pre-existing inventions and technologies are the separate property of VASCULAR BIOGENICS or BIOCLINICA and are not affected by this
Agreement, and neither Party shall have any claims to or rights in such separate pre-existing inventions or technologies of the other. It is also recognized and understood that in the event that any improvements or developments related to
BIOCLINICA’s own technology are created by BIOCLINICA during the performance of the Services under this Agreement, including but not limited to BIOCLINICA’s source code, or other unique methodology, and are not part of VASCULAR
BIOGENICS’ Intellectual Property Rights such improvements or developments shall be owned by BIOCLINICA. 
  

	4.	CONFIDENTIALITY 

 With respect to any and all information indicated as being or which
reasonably appears to be, of a confidential nature, including but not limited to protocols, data forms, material, study results and any proprietary information relating to a Party’s business, clinical trials activity, operations or products
acquired by a Party from the other Party as a result of this Agreement or from performance of the Services to be rendered hereunder, each Party agrees that it and its respective employees (i) will use the confidential information solely for the
purpose of this Agreement, (ii) will not use that information or disclose same to persons other than as may be necessary to carry out such Party’s duties hereunder and provided that such persons have been advised about the confidential
nature of the information and agreed to be bound by 

  
 2 

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

 
confidentiality; and (iii) will maintain the confidential information in secure location . VASCULAR BIOGENICS’ Intellectual Property Rights shall be considered VASCULAR BIOGENICS’
confidential information. The foregoing obligation shall not apply to information which the receiving Party can demonstrate that: 
  

	 	A.	Which is known to the receiving Party prior to its receipt thereof from the disclosing Party; 

  

	 	B.	Which is or lawfully becomes generally available to the public; 

  

	 	C.	Which is lawfully acquired from third parties who have a right to disclose such information; or 

  

	 	D.	Which by mutual agreement in writing of the Parties hereto is released from a confidential status. 

All employees of a Party who will have access to any of the foregoing information supplied by the disclosing Party have executed or shall have
executed prior to undertaking performance under this Agreement, agreements with the receiving Party requiring them to maintain in confidence all such information which they receive. 

 

	5.	RELATIONSHIP OF PARTIES 

 The relationship of BIOCLINICA to VASCULAR BIOGENICS is that of
an independent contractor and nothing in this Agreement shall be construed as creating any other relationship. 
  

	6.	AGREEMENT TERM/TERMINATION 

 The term of this Agreement is for the period of time
mutually agreed upon by VASCULAR BIOGENICS and BIOCLINICA and set forth in Exhibit A to complete the Services. 
 Termination of this
Agreement may be effected upon the giving of thirty (30) days written notice by VASCULAR BIOGENICS without any specified cause or reason. In the event that either Party commits a breach or default in any terms of this Agreement and such Party
fails to remedy the breach or default within thirty (30) days after notification of the breach or default from the other Party, the Party giving notice may, at its option and in addition to any other remedies it may have in law or in equity,
terminate this Agreement by sending written notice of immediate termination to the other Party. 
 In the event of a termination of this
Agreement, VASCULAR BIOGENICS will be responsible for payments for all work completed at that time of termination. In the event of such close down, BIOCLINICA shall furnish to VASCULAR BIOGENICS a written estimate of close-down costs. 

Upon the termination of the Agreement, BIOCLINICA shall return to VASCULAR BIOGENICS all VASCULAR BIOGENICS’ Data and confidential
information. For the sole purpose of determining the scope of obligations incurred under this Agreement, BIOCLINICA may retain, in a secure location and, to the extent possible, segregated from unrelated materials, a single archival copy of
Confidential Information returned to VASCULAR BIOGENICS. 
  

	7.	ARBITRATION 

 Any controversy or claim arising out of or relating to this Agreement, or
the breach thereof, which is not settled within a reasonable time, shall be settled by arbitration in accordance with the arbitration rules of the International Chamber Of Commerce (the “ICC Rules”) by one arbitrator appointed in
accordance with the ICC Rules. Any arbitration proceedings shall take place in London, England unless otherwise agreed. The award of the arbitrator shall be by majority vote (if more than one arbitrator was appointed in accordance with the ICC
Rules), shall be in writing and shall set forth the facts found by the arbitrator to exist. The arbitrator is authorized to grant pre-award and post-award interest at commercial rates. Notwithstanding

  
 3 

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

 
other provisions of this agreement which may be interpreted to the contrary, the arbitrator appointed herein shall not have the authority to grant damages to either party that are disclaimed or
limited under this agreement. Aside from the arbitrator’ fees and costs, which shall be shared equally by the parties unless the arbitrator for good cause determine otherwise, each party will be responsible for paying its own fees and
costs (including attorney’s fees) incurred in connection with such arbitration. Each party shall cooperate in providing fully to each other all requested information and documents relating to the arbitration proceedings, except for information
and documents subject to any privilege or to governmental export restrictions. The arbitration proceedings shall be conducted in the English language. The arbitral award must be consistent with the provisions of this Agreement and shall be
exclusive, final, and binding upon both Parties, and enforcement of the award may be carried out in any court or other body of competent jurisdiction. The award of any such arbitral tribunal shall be final and binding upon the parties. Each
Party acknowledges and agrees that any decision resulting from the arbitration proceedings contemplated hereunder would be enforceable in their respective countries and as specified by article 17. . 

 

	8.	INDEMNIFICATION 

  

	 	8.1	VASCULAR BIOGENICS Indemnification of BIOCLINICA 

 Except for any item for which
BIOCLINICA is responsible to indemnify VASCULAR BIOGENICS under Section 8.2, VASCULAR BIOGENICS agrees to defend, indemnify and hold harmless BIOCLINICA and its employees, agents, contractors and subcontractors against and from any claims
arising out of or in reference to the Services or for any claim arising out of bad faith, willful misconduct or negligent acts of VASCULAR BIOGENICS or its employees, agents, contractors and subcontractors or acts which are not in accordance with
the terms of this Agreement or with ethical practices of the consultations specified herein. VASCULAR BIOGENICS agrees to bear all costs and expenses, including reasonable attorney’s fees, incurred in connection with the defense of any such
claim. 
 VASCULAR BIOGENICS shall be promptly notified of any claim being made against BIOCLINICA and BIOCLINICA shall cooperate at the
request of VASCULAR BIOGENICS in the defense of such claim. VASCULAR BIOGENICS will not enter into any settlement agreement without the written consent of BIOCLINICA. 
  

	 	8.2	BIOCLINICA Indemnification of VASCULAR BIOGENICS 

 BIOCLINICA agrees to defend, indemnify
and hold harmless VASCULAR BIOGENICS and its employees and agents against and from any third party claims arising out of or in reference to the bad faith, willful misconduct or grossly negligent acts of BIOCLINICA and its employees, agents,
contractors and subcontractors or acts which are not in accordance with the terms of this Agreement or with ethical practices of the consultations specified herein. BIOCLINICA agrees to bear all costs and expenses, including reasonable
attorney’s fees, incurred in connection with the defense of any such third party claim. 
 BIOCLINICA shall be promptly notified of any
claim being made against VASCULAR BIOGENICS and VASCULAR BIOGENICS shall cooperate at the request of BIOCLINICA in the defense of such claim. BIOCLINICA will not enter into any settlement agreement without the written consent of VASCULAR BIOGENICS.

  
 4 

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

	9.	COMMUNICATIONS AND PAYMENTS 

 Any notice or other communication required or permitted
under this Agreement shall be in writing and shall be delivered by hand, first class mail, a nationally recognized overnight courier service, or facsimile transmission, to the Party at the address listed below or to any other address subsequently
specified by such Party in writing: 
 To BIOCLINICA: 

Mark L. Weinstein 
 President and
CEO 
 BIOCLINICA, INC. 
 826
Newtown-Yardley Road 
 Newtown, PA 18940 

Tel: (267) 757-3000 
 FAX:
(267) 757-3007 
 To VASCULAR BIOGENICS: 

Dr. Yael Cohen 
 VASCULAR
BIOGENICS LTD. 
 6 Jonathan Netanyahu Street, 

Or Yehuda, 60376 
 Israel 

Tel: +972-3-6346450 
 FAX:
+972-3-6346449 
 [***] 

[***] 
 Any such
notice shall be effective (i) in the case of hand delivery, when received; (ii) in the case of an overnight delivery service, on the next business day after being placed in the possession of such delivery service, with delivery charges
prepaid; (iii) in the case of the mail, three days after deposit in the postal system, first class postage prepaid; and (iv) in the case of facsimile transmission, when electronic indication of receipt is received. 

 

	10.	ASSIGNMENT 

 Neither Party shall have the right to assign this agreement or any of the
rights or obligations hereunder without the prior written consent of the other, such consent not to be unreasonably withheld; provided, however, either Party may make an assignment to an affiliate or to an assignee of that part of its business to
which this Agreement relates without the consent of the other Party, provided however that such party shall remain liable at all times for its obligations under this Agreement, including without limitation to the Confidentiality and intellectual
property rights obligations. In no event will such an assignment relieve VASCULAR BIOGENICS of its financial obligation under this Agreement, in the event that such affiliate or assignment fails to make payment as promised for herein. 

  
 5 

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

	11.	LIMITATION OF LIABILITY 

 In no event neither Party shall be liable to the other Party
for any special, exemplary, indirect, incidental, consequential or punitive damages of any kind or nature whatsoever. 
  

	12.	HEADINGS 

 All section headings and sub-headings are for convenience only and do not in
themselves define a scope of work or specific terms or conditions of this Agreement. 
  

	13.	ENTIRE AGREEMENT 

 This Agreement, including Exhibit A, constitutes the entire Agreement
between the Parties and, except as specified herein, supersedes all prior contracts, agreements and understandings relating to the same subject matter between the Parties. The Parties intend this Agreement to be a complete statement of the terms of
their Agreement and no change or modification of any of the provisions of this Agreement shall be effective unless it is in writing and signed by a duly authorized officer of BIOCLINICA and VASCULAR BIOGENICS. 

 

	14.	WAIVER 

 The failure of a Party in any instance to insist on the strict performance of
the terms of this Agreement shall not be construed to be a waiver or relinquishment of any terms of this Agreement, either at the time of the Party’s failure to insist upon strict performance or at any subsequent time, and such terms shall
continue in full force and effect. 
  

	15.	SEVERANCE 

 Each clause of this Agreement is a distinct and severable clause and if any
clause is deemed illegal, void, or unenforceable, the validity, legality, or enforceability of any other clause or portion of this Agreement shall not be affected thereby. 
  

	16.	GOVERNING LAW 

 The construction and performance of this Agreement shall be governed by
the laws of England. 
  

	17.	SURVIVAL 

 Sections 2, 3, 4, and 6 through 16 will survive termination or expiration of
this Agreement. 
 In WITNESS WHEREOF, the undersigned Parties have executed this Agreement on the dates set forth below. 

 

									
	BioClinica, Inc.	 		 	Vascular Biogenics Ltd.
					
	By:	 	/s/ Maria T. Kraus	 		 	By:	 	/s/ Amos Ron
					
	Print:	 	Maria T. Kraus	 		 	Print:	 	Amos Ron
					
	Title:	 	VP & Corporate Controller	 		 	Title:	 	CFO
					
	Date:	 	24-Sep-2012	 		 	Date:	 	September 24, 2012

  
 6 

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

  
 

 
 Exhibit A 

Vascular Biogenics Ltd. 

Medical Imaging Core Laboratory Services in Support of 

a Study Entitled: “A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed 

by a 12-Week Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in 

Patients with Mild to Moderate Ulcerative Colitis.” 

BioClinica Agreement #40801 

Prepared for: 
 Vascular
Biogenics Ltd. 
 6 Jonathan Netanyahu Street 

Or Yehuda, Israel 60376 

July 13, 2012 / Version 1 

August 24, 2012 / Version 2 

September 20, 2012 / Version 3 
 BioClinica,
Inc., 826 Newtown Yardley Road, Newtown, PA 18940, www.bioclinica.com 
 This document contains information that is confidential and proprietary to
Vascular Biogenics Ltd. and BioClinica, Inc. 
 It has been prepared solely for the information of Vascular Biogenics Ltd. and BioClinica, Inc. and
therefore should not be duplicated or otherwise made available to third parties. 

  

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 TABLE OF CONTENTS 
  

							
	 EXECUTIVE SUMMARY
	  	 	3	  
			
	 1.
	 	PROJECT SCOPE OF WORK	  	 	4	  
			
	 1.1.
	 	 SCOPE OF WORK
	  	 	4	  
			
	 1.2.
	 	 PROJECT TIMELINE ASSUMPTIONS
	  	 	5	  
			
	 2.
	 	CORE LABORATORY SERVICES	  	 	5	  
			
	 2.1.
	 	 STUDY PREPARATION, SITE SET-UP AND STANDARDIZATION
	  	 	5	  
			
	 2.2.
	 	 CENTRALIZED IMAGE DATA TRACKING AND QUALITY CONTROL
	  	 	7	  
			
	 2.3.
	 	 IMAGE INTERPRETATION SERVICES
	  	 	7	  
			
	 2.4.
	 	 DATA MANAGEMENT SERVICES
	  	 	10	  
			
	 2.5.
	 	 PROJECT ADMINISTRATION
	  	 	11	  
			
	 2.6.
	 	 PROJECT CLOSE-OUT SERVICES
	  	 	13	  
			
	 2.7.
	 	 REGULATORY COMPLIANCE
	  	 	13	  
			
	 3.
	 	PROJECT FEES AND EXPENSES	  	 	14	  
			
	 3.1.
	 	 PROJECT FEES
	  	 	14	  
			
	 3.2.
	 	 EXPENSES
	  	 	16	  
			
	 3.3.
	 	 OVERALL TOTAL PROJECT BUDGET
	  	 	17	  
			
	 4.
	 	PAYMENT SCHEDULE AND BILLING	  	 	17	  

  
 

 
 2 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 EXECUTIVE SUMMARY 

COMPANY OVERVIEW 

BioClinica, established in 1990, is an independent, financially stable, global clinical trials service organization, specializing in medical image management
and eClinical services. The services include, site standardization, medical image collection and quality control, independent review, electronic data capture, IVR/IWR and clinical data management solutions for pharmaceutical, medical device
companies and other organizations, including contract research organizations. BioClinica is a publicly traded corporation listed on the NASDAQ Global Market under the symbol BIOC. BioClinica has over 20 years of experience in providing comprehensive
design and management of the medical imaging portion of clinical trials worldwide. 
 Please refer to Appendix A to learn more about our
eClinical service offerings 
 MAIN OFFICE LOCATIONS 

BioClinica’s HQ is located at 826 Newtown-Yardley Road, Newtown, PA 18940, USA. 

Additional BioClinica offices involved in Image Management are located in: 
  

	 	•	 	Leiden, The Netherlands (European Headquarters & imaging core laboratory) 

  

	 	•	 	Lyon, France (software development for image analysis) 

  

	 	•	 	Tianjin, China (Medical Image Management) 

 KEY
DIFFERENTIATORS 
 The key differentiators that separate BioClinica from our competitors are: 

 

	 	•	 	Publicly traded company audited by PricewaterhouseCoopers – this offers our clients financial transparency and reassurance on our company’s reliability for their long-term clinical trial projects.

  

	 	•	 	Full service imaging core lab locations in Europe and the USA which is critical for managing global studies due to language barriers and various time zones. Our 24/7 multilingual contact center offers around the clock
support. 

  

	 	•	 	We support ALL imaging modalities and therapeutic areas with certified technologists and highly experienced, trained Readers. 

  

	 	•	 	BioClinica has a network of approximately 106 expert readers across all therapeutic areas. This network of readers has active confidentiality agreements and executed contracts. 

 

	 	•	 	Project Managers are highly skilled, focusing on setting expectations via strong communication skills and pro-activeness via risk management. The Project Management teams are aligned by therapeutic areas which allow the
project managers to utilize their prior experiences in developing risk management plans. 

  

	 	•	 	Led by an extremely stable Management team - the President of BioClinica has been with the company since 1997 and the average tenure of the Bio-Imaging division senior manager is 10+ years. 

STUDY EXPERIENCE 

BioClinica has extensive experience in supporting international multi-center clinical trials in the therapeutic areas of oncology, neurology, cardiology,
endocrinology, gastrointestinal, women’s health, inflammation and orthopedics. 
 Inflammatory Bowel Diseases; Crohn’s and Ulcerative Colitis
study Experience: 
 BIOCLINICA is presently performing an endoscopy trial with 60 global sites and over 100 patients. 

In the past we have performed trials in Crohn’s disease and Ulcerative Colitis with different imaging modalities such as Ultrasound, MRI and Endoscopy,
with patients ranging form 20-150 and sites ranging from 4 to 100. 
 [***] 

POINTS FOR CONSIDERATION 

BioClinica would welcome the opportunity to discuss the set-up in a meeting with Vascular Biogenics Ltd to design the imaging part of the project in the best
possible way. There are several options for the set-up and the decision depends on the value and the associated costs and is best discussed in a meeting. 

  
 

 
 3 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	1.	PROJECT SCOPE OF WORK 

 Vascular Biogenics Ltd. (hereinafter referred to as
“VASCULAR BIOGENICS”) has requested that BioClinica, Inc. and subsidiaries (hereinafter referred to as “BIOCLINICA”) provide medical imaging core laboratory services in support of an Ulcerative Colitis Study. 

 

	1.1.	[***] 

  
 

 
 4 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 [***] 
  

	1.2.	[***] 

  

	2.	CORE LABORATORY SERVICES 

  

	2.1.	STUDY PREPARATION, SITE SET-UP AND STANDARDIZATION 

  

	2.1.1.	Study Set-Up 

 If available, VASCULAR BIOGENICS will provide BIOCLINICA with the final
study protocol and subsequent amendments at the start of the study. 
 BIOCLINICA will perform the following services upon commencement of
the study: 
  

	 	•	 	Preparation and set-up of internal clinical trial and regulatory files 

  

	 	•	 	Preparation and set-up of required folders on the BIOCLINICA network 

  

	 	•	 	Preparation and set-up of project specific BioPACSTM database 

 BioPACSTM is a custom
designed enterprise system that provides image management and workflow, query capabilities, inventory and image archival, site and project management tools to automate and accelerate the process of evaluating images generated during a clinical
trial. The BioPACSTM Image Core Laboratory technology system complies with FDA 21 CFR Part 11 requirements and adheres to the industry DICOM standard for compatibility with image viewers and other analysis software. 

 

  
 

 
 5 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 BIOCLINICA will provide VASCULAR BIOGENICS with access to the BioPACSTM web portal which
will allow VASCULAR BIOGENICS to view study documents, access real time project reports and follow the course of study progression within BIOCLINICA. The Web Portal will be password protected and VASCULAR BIOGENICS will have twenty-four
(24) hour access to the site. 
 BIOCLINICA will establish a password protected FTP account for each site. The sites will submit 50% of
the data to BIOCLINICA via FTP server. 
  

	2.1.2.	Site Technical Evaluation and Coordination 

 BIOCLINICA will create a study specific site
technical survey in an effort to capture all necessary contact and equipment information. BIOCLINICA will contact each of the sites to: 
  

	 	•	 	Identify the technologist(s) who will be responsible for protocol implementation at each site 

  

	 	•	 	Review the site’s imaging equipment at the site 

  

	 	•	 	Review the site’s data transfer capabilities and archival procedures 

 Upon receipt of the
completed site survey, a BIOCLINICA technologist will review the technical information and verify overall completeness. All site interaction will be logged, indicating the date the site was contacted, the method of contact and the number of
communication attempts. In the event that any follow up or action items are required as a result of the site survey, BIOCLINICA will capture all related information in the tracking database. 

If site equipment (hardware or software) is upgraded or changed during the course of the study, it will be the site’s responsibility to
inform BIOCLINICA of the upgrade. 
  

	2.1.3.	Development of Imaging Manual 

 BIOCLINICA will develop an imaging manual including image
acquisition guidelines, site procedures for image transfer (courier or electronic) and image data transmittal forms (paper or electronic). These forms are required to establish an image data audit trail and are utilized by BIOCLINICA during the data
collection and quality control process. 
  

	2.1.4.	Study Kit Preparation and Provision to Sites 

 BIOCLINICA will prepare a study kit for
delivery to the participating sites. The study kit will contain the imaging manual, supply re-order forms, sample data transmittal forms, a BIOCLINICA contact list, and for sites submitting data via courier, pre-addressed courier waybills, archival
media, padded mailers and/or courier mailers. In addition to containing the imaging binder, the study kit may contain other client approved study specific materials that are needed per the protocol. 

 

	2.1.5.	Investigator’s Meeting Preparation and Presentation 

 A BIOCLINICA Project Manager
will attend and present at the Investigator’s Meeting(s) organized by VASCULAR BIOGENICS. 
 BIOCLINICA will prepare a PowerPoint
presentation to be presented during the meeting which will include the study requirements, imaging guidelines and the process for submission of data to BIOCLINICA. BIOCLINICA will provide the presentation to VASCULAR BIOGENICS prior to the meeting
for review and approval. BIOCLINICA will also prepare any supporting materials that are required for the meeting. (e.g. handouts, sample binders). 

  
 

 
 6 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 During the meeting, BIOCLINICA will review the presentation and field any questions.
Reasonable travel costs and expenses for the meeting will be billed separately. BIOCLINICA has assumed a project manager will be the designated representative at the Investigator’s Meeting. 

 

	2.2.	CENTRALIZED IMAGE DATA TRACKING AND QUALITY CONTROL 

 BIOCLINICA has assumed that all
image data for a given timepoint will be sent to BIOCLINICA from the sites as the timepoints are completed. Timely quality assurance of the data is not possible if data are not received in a timely manner. BIOCLINICA will notify VASCULAR BIOGENICS
of data transmittal delays and of the potential impact on BIOCLINICA timelines if the delays are not corrected. 
  

	2.2.1a.	Image Data Log-In 

 Upon receipt of the data, BIOCLINICA will review the
demographic data (e.g. patient number, site number, scan date, timepoint description, imaging modality etc.) provided by the site and will perform a verification check that the correct image data has been received. The data will be uploaded into
BioPACSTM. Any discrepancies between the data received and the information provided by the site will be resolved directly with the site. 
  

	2.2.1b.	Image Data Quality Control 

 Image data quality control will be performed by
certified radiologic technologists. All image data will be saved into a standard file format (typically DICOM), so that the images may be read and archived digitally. This process may include the following tasks: 

 

	 	•	 	Anonymization of imaging data (e.g. removal of site, subject, timepoint identifiers etc.) 

  

	 	•	 	Conversion of digital image data into a standard file format 

  

	 	•	 	Quality Control of the image data for protocol compliance 

  

	 	•	 	Process endoscopy image data including selection of clips and streaming video to match read / analysis criteria 

  

	 	•	 	Generate labels for the masked videotapes and prepare for use in the independent review 

  

	 	•	 	Notification to VASCULAR BIOGENICS and participating sites of technical imaging adequacy issues and recommendation of appropriate action(s) to resolve the issues 

 

	 	•	 	Fax/E-mail notification to site and VASCULAR BIOGENICS of Test Data 

 BIOCLINICA will generate a
query in the event that data discrepancies are noted during the QC of the image data, which is performed by a certified radiologic technologist. The query is generated to document the following issues, but is not limited to, data quality, protocol
compliance issues and missing data. 
 The query process includes the following: 

 

	 	•	 	Preparation of a query including documentation of the issue 

  

	 	•	 	Preparation and shipment of letter or email to site and VASCULAR BIOGENICS documenting the query 

  

	 	•	 	Resolution and filing of query documentation 

  

	2.3.	IMAGE INTERPRETATION SERVICES 

  

	2.3.1.	Image Review Application Development and Validation 

 BIOCLINICA will develop a custom
application, BioREADTM, to execute the independent image review session. The development of this application will include the following: 
  

	 	•	 	Creation of a client business requirements specification document 

  

	 	•	 	Creation of a technical design specification document 

  

	 	•	 	Programing of the BioREADTM application 

  
 

 
 7 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	 	•	 	Full unit testing 

  

	 	•	 	Test script development and execution of test plan 

  

	 	•	 	Validation report 

  

	 	•	 	User acceptance testing 

 BIOCLINICA will work in collaboration with VASCULAR BIOGENICS to
design this application. The timeline for the delivery of the application and the milestones for key deliverables (e.g. business requirements document) will be agreed upon by VASCULAR BIOGENICS and BIOCLINICA. 

 

	2.3.2.	Image Interpretation Training Session 

 BIOCLINICA will conduct a training session prior
to the first image interpretation session. Representatives from BIOCLINICA’s Project Management, Clinical Operations and Technical Services departments will attend and participate in this session. The training session is conducted in part for
the purpose of familiarizing both VASCULAR BIOGENICS personnel and the reader(s) with the image review application as well as the independent image review design. During this meeting, VASCULAR BIOGENICS personnel and the independent reader(s)
will review the operation of the BioREADTM application, including the interrelationship between questions, sessions, and image display utilizing non-study subjects with relevant image sets. The BioREADTM application is a custom-designed
system that provides full automatic image display capabilities for independent reads and captures the reader’s interpretation and image evaluation all in one solution. 

BIOCLINICA will develop a Read Rules Document. This document will include an overview of the clinical protocol, imaging requirements, and image
review application questions/answers. It will also include rules for each reader to follow when completing the read electronic case report form (eCRF). This document will be developed by BIOCLINICA’s Clinical Operations personnel and reviewed
by both reader(s) and VASCULAR BIOGENICS. 
  

	2.3.3.	Conduct and Monitoring of the Image Interpretation Session 

  

	2.3.3a.	Performance of Image Review Sessions and Management of Independent Readers 

 The
review of the image data will be performed by independent readers not affiliated with the study either at the location of the independent reader or at a BIOCLINICA site. All reader image assessments will be captured electronically within the
BioREADTM application. 
 The following services will be performed in conjunction with the image review session: 

 

	 	•	 	Testing of BioREADTM System (hardware and software) 

  

	 	•	 	Loading of the timepoints for the given image review session to the BioREADTM application 

  

	 	•	 	Independent reader training, including review of reader rules prior to the first read session 

  

	 	•	 	Image review application back-up and export of reader image interpretations 

 All costs related
to this service include BIOCLINICA licensing fees for the use of the BioREADTM application during the image interpretation sessions. BIOCLINICA will procure the equipment that will be utilized during the image review sessions and will deploy the
equipment and the image review application to the off-site read locations, if necessary. BIOCLINICA will provide technical support to the readers during the off-site read sessions. 

Leasing fees are included for the use of the equipment as well as any related costs for dedicated communications lines that are required for
remote reading sessions, in order to retrieve the data assessed by the readers from their remote location. 

  
 

 
 8 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 BIOCLINICA will notify the site and VASCULAR BIOGENICS via fax or e-mail of patient
eligibility results as well as the rolling read results within 3 – 5 business days of data receipt at BIOCLINICA (excluding public holidays and weekends). BIOCLINICA will notify the site and VASCULAR BIOGENICS via fax or e-mail of the results
from the secondary read within 5 – 8 business days of data receipt at BIOCLINICA (excluding public holidays and weekends). 
  

	2.3.3b.	Image Review Monitoring Plan 

 BIOCLINICA will perform an evaluation of the image
review results to monitor read quality. Monitoring is also performed to ensure adherence to the response criteria as defined in the Imaging Charter, the Read Rules Document and the VASCULAR BIOGENICS clinical protocol. This evaluation will be
conducted on an agreed upon basis as deemed appropriate by BIOCLINICA and as per the monitoring plan. 
 If necessary, BIOCLINICA and
VASCULAR BIOGENICS will make a joint decision to determine if retraining of the reader is deemed appropriate. If so, BIOCLINICA will conduct a training session to review specific cases. 

Further discussion is required between BIOCLINICA and VASCULAR BIOGENICS in order to finalize the image read plan. 

 

	2.3.4.	Final Study Report 

 BIOCLINICA will prepare a study report, which will include: 

 

	 	•	 	Protocol Overview 

  

	 	•	 	Project Summary 

  

	 	•	 	Summary of Subject Assessments 

  

	 	•	 	Receipt and Preparation of Image Data for Image Review 

  

	 	•	 	Description of the image review application 

  

	 	•	 	Image Interpretation Training Session and Reader Training/Qualification 

  

	 	•	 	Image Interpretation Sessions 

  

	 	•	 	Transfer of Data to VASCULAR BIOGENICS 

 Appendices may include the following documents: 

 

	 	•	 	Imaging Charter 

  

	 	•	 	Listing of Image Data Received 

  

	 	•	 	Business Requirements Specification Document 

  

	 	•	 	Applicable Note to File(s) 

  

	 	•	 	Curriculum Vitae of Radiologists and Designated Experts 

  

	 	•	 	Read Rules Document 

  

	 	•	 	Image Review Monitoring Plan 

  

	 	•	 	Listing of Subjects Read 

  

	 	•	 	Data Export Specifications Document 

 *Please note the Final Study Report does not include a
statistical analysis of the data. 
 BIOCLINICA shall deliver the study report to VASCULAR BIOGENICS within thirty (30) business
days following completion of the final data transfer. VASCULAR BIOGENICS will have a review period of thirty (30) business days, following delivery of the report. Within this period, VASCULAR BIOGENICS may request within-scope revisions to the
report and BIOCLINICA will make requested within-scope revisions at no additional cost to VASCULAR BIOGENICS. 

  
 

 
 9 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	2.4.	DATA MANAGEMENT SERVICES 

  

	2.4.1.	Development & Validation of Export Program 

 The results obtained from the
independent image review session will be provided to VASCULAR BIOGENICS in BIOCLINICA’s standard export format, SAS datasets. BIOCLINICA will provide a detailed export specification document describing the data sets to be provided. Upon written
approval of this specification document by VASCULAR BIOGENICS, BIOCLINICA will begin the programming and validation of the export program. 

In the event VASCULAR BIOGENICS requests a custom export format, the export specification will be developed by BIOCLINICA in collaboration with
VASCULAR BIOGENICS. The additional time and costs associated with a custom export are not reflected in this agreement. VASCULAR BIOGENICS will be notified of such increases in writing for approval. 

 

	2.4.2.	Data Cleaning and Maintenance 

 BIOCLINICA will work in collaboration with VASCULAR
BIOGENICS at the start of the study to define protocol-specific fields to be checked at regularly scheduled intervals. This includes but is not limited to the following: 
  

	 	•	 	Comparison of demographic information (Site, Subject, Initials, Exam Date(s), etc.) collected by BIOCLINICA against those provided by the client enrollment log 

 

	 	•	 	Chronological date progression (e.g., ensure that the date of Visit 2 is later than Visit 1, no images acquired after a Date of Death if applicable.) 

 

	 	•	 	Data derived by the independent image review application 

 Standard Edit Checks 

Standard edit checks are composed of checks for technical quality such as identifying duplicate records within a table and table-to-table
comparisons by key parameters (e.g. site number, subject number) to assure subjects appear in all applicable tables. These checks also compare and reconcile key parameters of the data housed in BioREADTM compared to BioPACSTM. 

Study Specific Checks 

Study-specific edit checks are developed for each study based on the response criteria that is utilized as well as other study related
requirements that are defined in the Read Management Plan. 
 Edit Check Management 

Edit Checks are performed regularly on the image read data to allow identification of any data discrepancies. Any data discrepancies noted in
the output are investigated by a BIOCLINICA Clinical Data Manager to identify the reason for the output. The Clinical Data Manager works with the internal project team (Medical Affairs, Clinical Operations, Applications Development, Clinical
Application Technical Services, and Project Management) to resolve data discrepancies appropriately. If any database updates are performed in resolving the discrepancies, the edit checks are re-run to insure no new issues arise. This is an iterative
process and continues until all edit checks are resolved. 
  

	2.4.3.	Data Export 

 BIOCLINICA will export data as SAS datasets unless otherwise specified.
BIOCLINICA will perform a final QC of the data prior to submission to VASCULAR BIOGENICS. 
 BIOCLINICA will perform a transfer of test data
to ensure that VASCULAR BIOGENICS can successfully receive data and the data meets the provisions of the specification document. The final data will be sent to VASCULAR BIOGENICS within ten (10) business days after all the data for a given
export has been acquired. 

  
 

 
 10 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 If required, BIOCLINICA will follow up with VASCULAR BIOGENICS on issues related to each
given export up until ninety (90) days post project completion as defined in Table 1.2. In the event export questions are received after this period, VASCULAR BIOGENICS will be billed on an ad-hoc basis as deemed appropriate by BIOCLINICA.
BIOCLINICA will not perform any research or follow up on these inquiries without written authorization from VASCULAR BIOGENICS to proceed. 
  

	2.5.	PROJECT ADMINISTRATION 

  

	2.5.1.	Project Management Services 

 BIOCLINICA will provide in-house project management and
administration for this project. A project manager and project team will be assigned to the study. This team may include the representatives from the following departments: 
  

	 	•	 	Project Management 

  

	 	•	 	Medical Affairs 

  

	 	•	 	Clinical Operations 

  

	 	•	 	Core Laboratory 

  

	 	•	 	Product Development 

  

	 	•	 	Regulatory 

  

	 	•	 	Data Management 

  

	 	•	 	Administrative support staff, as necessary 

 The assigned project manager serves as the primary
contact for the project. The project manager oversees the day to day operations for projects in-house at BIOCLINICA. Regular internal project meetings are organized by the project manager to monitor resource planning and project progress.
Administrative personnel provide support to the project managers and are included in the project management fee. 
 Additional
responsibilities include: 
 Communication Plan 

The project manager will develop a project communication plan that will describe the processes that will be followed during the course of the
study including the levels of communication between BIOCLINICA, VASCULAR BIOGENICS, and other project related vendors. In addition, this document will outline details of the process to be followed for project issue resolution. 

Teleconferences 
 The
BIOCLINICA project manager will participate in teleconferences as needed with VASCULAR BIOGENICS to discuss the overall project progress, issues, timelines etc. The frequency and duration of the teleconferences may vary during the course of the
study. 
 Work Instruction Development 

The project manager will be responsible for the development of an internal project specific work instruction manual. The purpose of this manual
is to provide BIOCLINICA employees a detailed description of the procedures to be utilized during the course of the study. 

  
 

 
 11 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	2.5.2.	Project Reporting Services 

 Web portal Reporting 

BIOCLINICA will provide real time access to the web portal in order for VASCULAR BIOGENICS to have appropriate status updates. Presented below
are standard summary reports: 
  

	 	•	 	Project Start up Report – study startup details including the status of the site surveys and study kits 

  

	 	•	 	Collection of Site Data Report – a detail listing of the responses, by the site, on the site surveys 

  

	 	•	 	Image Status Report – details regarding data received, individual modalities received per timepoint, missing image data and query status, study sequence listings 

 

	 	•	 	Query Status Report – report displaying all outstanding queries as well as resolved queries 

  

	 	•	 	Read Summary Report – detailed information related to the project read status, including patient/timepoint/modality reviewed 

  

	 	•	 	Project Metrics Report – a multifunctional report providing predefined metrics and projections including averages and study targets 

 

	 	•	 	Program Metrics Report – predefined metrics including averages and study targets defined with metrics presented as collected on a monthly basis 

Metrics Champion Consortium (MCC) 

BIOCLINICA is an active member of the MCC, which is an organization that develops performance metrics within the Biotechnology and
Pharmaceutical industry with the intent to jointly encourage performance improvement, effectiveness, efficiency, and appropriate levels of controls for both VASCULAR BIOGENICS and Service Providers in support of the drug development process. 

BIOCLINICA participates in the continuous collaborative development of standardized performance metrics including process improvement tools. As
a result, BIOCLINICA can provide the Imaging Metrics Report to VASCULAR BIOGENICS throughout the duration of the study. 
  

	2.5.3.	Site Management and Image Archival Services 

 Site Management 

BIOCLINICA will provide support services to manage, monitor and coordinate the imaging acquisition, collection and query resolution portion of
the study. BIOCLINICA will interact directly with the site on image data tracking, follow-up on issues as necessary and maintain the image audit trail. Communication with the sites will be documented appropriately. 

VASCULAR BIOGENICS will be responsible for providing BIOCLINICA with patient enrollment updates as well as participating site lists on an
ongoing basis. These updates should visibly indicate new information since the last send. Incremental updates are preferred or if cumulative updates are sent all incremental changes from the prior report should be identified. 

Based on enrollment logs sent from VASCULAR BIOGENICS, BIOCLINICA will follow up with each participating site on an ongoing basis regarding
site surveys, outstanding image data and image data related queries. In the event that a site becomes unresponsive, BIOCLINICA will inform and seek assistance from VASCULAR BIOGENICS. 

Data Back-up and Archive 

Throughout the study an image data back-up will be performed on data storage systems. Off-site image data back-up will also be performed at two
(2) geographically distant sites. Other electronic data (electronic CRFs, audit trails, database contents, electronic documents, etc.) will be stored on a dedicated database server and saved daily throughout the study, via a secure network
connection at two (2) different geographical sites. 

  
 

 
 12 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 All study data will be digitally archived in compliance with ICH Guidelines for at least 15
years at study end. Additional costs will apply for this long term archive and a separate cost estimate will be provided at the end of the study, based on the actual total size of the data to be archived (digital and paper data). 

Audit Trails 
 BIOCLINICA
will consistently maintain an audit trail for each step of image data collection, quality control, processing, image interpretation assessment, central and off-site archiving procedures and all site communication in compliance with the applicable
regulatory requirements including GCP and FDA’s 21 CFR part 11. 
  

	2.6.	PROJECT CLOSE-OUT SERVICES 

  

	2.6.1.	Project Close-Out 

 Upon completion of the study, BIOCLINICA will perform independent
departmental study close-out procedures. Project close-out procedures may include the following services: 
  

	 	•	 	Archive the study materials and destroy any excess supplies 

  

	 	•	 	Collate all study files which may include; correspondence, Notes to Files, DTFs etc... and forward to BIOCLINICA’s Records Management department 

 

	 	•	 	Archive all study data from BIOCLINICA network to digital media; one (1) copy will be sent to long-term off-site storage. The storage facility is a secure environmental controlled facility. 

 

	 	•	 	Perform official close-out of study-specific administrative accounts including generation of final invoice 

BIOCLINICA’s Records Management department will facilitate the close-out process by organizing and cataloging project related documents,
including any regulatory or internal BIOCLINICA filings. These materials will be stored off-site in long-term storage for fifteen (15) years. After the fifteen (15) year retention period, BIOCLINICA will have the materials destroyed in
accordance with the appropriate Standard Operating Procedures and Work Instructions. 
 BIOCLINICA assumes that all original image data sent
to BIOCLINICA will be returned to VASCULAR BIOGENICS upon completion of the project or sooner if no longer required by BIOCLINICA. Original image data is defined as the source data, acquired at the sites, that is forwarded to BIOCLINICA after the
patient has been imaged for a specific timepoint. BIOCLINICA will need ample notice to comply with the request, should VASCULAR BIOGENICS require the image data to be blinded prior to shipping. In the event VASCULAR BIOGENICS requires all original
image data to be sent back to the sites, additional courier fees will apply. 
  

	2.7.	REGULATORY COMPLIANCE 

 BIOCLINICA’s custom designed enterprise system,
BioPACSTM, provides Image Core Laboratory technology of image, workflow, query, inventory, site and project management tools to automate and accelerate the process of evaluating images generated during a clinical trial. This system complies with
FDA 21 CFR Part 11 requirements. 
 An audit trail will be consistently maintained for each step of the BIOCLINICA process in compliance with
the applicable regulatory requirements including Good Clinical Practice (GCP) and FDA 21 CFR part 11. 

  
 

 
 13 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	3.	PROJECT FEES AND EXPENSES 

  

	3.1.	PROJECT FEES 

 The estimated fees provided below are based upon the specific assumptions
found within this document. Material alterations to the assumptions, including, but not limited to, a change in the number of patients, amount of data, level of support services or timeline, will impact final pricing. BIOCLINICA will only charge
pro-rata for work performed at the rates quoted. BIOCLINICA fees will increase annually beginning with month 25 of the project as defined by the actual project start date. This increase will be equivalent to the percent increase in the Euro
Harmonized Index of Consumer Prices (HICP). 
 In the event the study is canceled, BIOCLINICA will not charge a cancellation fee. 

All the fees presented below are based on preliminary assumptions. Once a final protocol has been established, BIOCLINICA will collaborate
with VASCULAR BIOGENICS on the image review design and the analyses required. Based on the outcome of these discussions BIOCLINICA may submit a revised proposal to VASCULAR BIOGENICS in which fees may be modified. 

 

	3.1.1.	[***] 

  
 

 
 14 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 [***] 

  
 

 
 15 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	3.2.	[***] 

  

	3.2.1.	[***] 

  

	3.2.2.	[***] 

  
 

 
 16 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	3.3.	[***] 

  

	4.	[***] 

  
 

 
 17 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

  
 

 
 Vascular Biogenics Ltd. 

Medical Imaging Core Laboratory Services in Support of 

a Study Entitled: “A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed 

by a 12-Week Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in 

Patients with Mild to Moderate Ulcerative Colitis.” 

Prepared for: 
 Vascular
Biogenics Ltd. 
 6 Jonathan Netanyahu Street 

Or Yehuda, Israel 60376 

BioClinica Addendum #40801_1 

November 19, 2012 

BioClinica, Inc., 826 Newtown Yardley Road, Newtown, PA 18940, www.bioclinica.com 

This document contains information that is confidential and proprietary to Vascular Biogenics Ltd. and BioClinica, Inc. It has been prepared solely for the
information of Vascular Biogenics Ltd. and BioClinica, Inc. and therefore should not be duplicated or otherwise made available to third parties. 

  

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 TABLE OF CONTENTS 
  

					
	 1. SCOPE OF WORK
	  	 	3	  
		
	 1.1. ADDENDUM ASSUMPTIONS
	  	 	3	  
		
	 2. ADDENDUM PROJECT FEES AND EXPENSES
	  	 	4	  
		
	 2.1. ADDENDUM PROJECT FEES
	  	 	4	  
	 2.2. ADDENDUM EXPENSES
	  	 	5	  
	 2.3. BILLING POLICY
	  	 	6	  
		
	 3. TERMS AND CONDITIONS
	  	 	7	  

  
 

 
 2 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	1.	SCOPE OF WORK 

 Vascular Biogenics Ltd. (hereinafter referred to as “VASCULAR
BIOGENICS”) has requested that BioClinica, Inc. and subsidiaries (hereinafter referred to as “BIOCLINICA”) provide additional medical imaging core laboratory services in support of an Ulcerative Colitis study. 

This Addendum serves to document the additional services requested for this study beyond those contained within the following: 

 

	 	•	 	Agreement #40801 between BIOCLINICA and VASCULAR BIOGENICS, executed 24 September 2012 

This Addendum also serves to document the fees for the additional services. 

 

	1.1.	ADDENDUM ASSUMPTIONS 

 Presented below is an outline of the additional and modified
services requested by VASCULAR BIOGENICS for an Ulcerative Colitis study that are not included within the original agreement. 
  

	 	•	 	Additional two (2) sites, one (1) in Poland and one (1) in Hungary. 

  

	 	•	 	Added one (1) web-based Image Interpretation Training session for eligibility. 

  

	 	•	 	One hundred fifty-eight (158) fewer timepoints prepared for review. 

  

	 	•	 	One hundred ten (110) fewer screening timepoints as screening will be prepared for review only once. 

  

	 	•	 	Sixty-six (66) fewer timepoints re-read by a second reader if there is a discrepancy between the local and central review. 

  

	 	•	 	Addition of 10% of screening timepoints (12 timepoints) reviewed by a second reader for eligibility plus 5% of screening timepoints (6 timepoints) reviewed for the primary review if read by the third reader.

  

	 	•	 	One hundred ten (110) fewer fax/e-mail notifications to site and VASCULAR BIOGENICS of rolling read results as screening will be read only once. 

 

	 	•	 	Forty-eight (48) fewer fax/e-mail notifications to site and VASCULAR BIOGENICS of secondary read results. 

  

	 	•	 	Removal of 20% or sixty-six (66) timepoints re-read by a second reader if there is a discrepancy between the local and central review. 

 

	 	•	 	Addition of 10% of screening timepoints (12 timepoints) reviewed by a second reader for eligibility plus 5% of screening timepoints (6 timepoints) reviewed for the primary review if read by the third reader.

  

	 	•	 	Applicable pass-through and reader fees. Reader fees are updated to reflect US Dollars. 

Eligibility Review: 
  

	 	•	 	One (1) additional reader for a total pool of three (3) readers, sharing the workload, for the eligibility review. 

  

	 	•	 	Screening timepoints will be re-read by a second reader for screening timepoints with a score of < 2, assuming 10% of timepoints will be re-read. 

Primary Review: 
  

	 	•	 	One (1) reader from a pool of two (2) readers for the primary review. 

  

	 	•	 	Each screening timepoint will only be read once for eligibility review and then count as baseline in the primary review assuming the same two (2) readers that are reading for eligibility are the same as the primary
review. Timepoints read by the third reader for eligibility will be re-read by reader one (1) or two (2) in the primary review, assuming 5% of timepoints will be re-read. 

 

	 	•	 	Removal of 20% of timepoints re-read due to a discrepancy between the local and central assessment. 

  

	*	All other assumptions from Original Agreement #40801 will remain the same. 

  
 

 
 3 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	2.	ADDENDUM PROJECT FEES AND EXPENSES 

  

	2.1.	ADDENDUM PROJECT FEES 

 The fees for services detailed within this Addendum are
summarized below. BIOCLINICA will only charge pro-rata for work performed at the rates quoted. 
 As per the original agreement, BIOCLINICA
fees will increase annually beginning with month 25 of the project as defined by the actual (original) project start date. This increase will be equivalent to the percent increase in the Euro Harmonized Index of Consumer Prices (HICP). 

 

	2.1.1.	[***] 

  

	2.1.2.	[***] 

  
 

 
 4 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	2.2.	[***] 

  

	2.2.1.	[***] 

  

	2.2.2.	[***] 

  

	2.2.3.	[***] 

  
 

 
 5 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 [***] 
  

	2.2.5.	[***] 

  

	2.3.	BILLING POLICY 

 The above mentioned fees will continue to be billed to VASCULAR
BIOGENICS on a monthly basis and will include relevant back-up documentation. 

  
 

 
 6 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	3.	TERMS AND CONDITIONS 

 All services will be performed by BIOCLINICA as an Addendum to
BIOCLINICA Agreement #40801, and all terms and conditions of Agreement #40801 shall apply. 
  

									
	 AGREED AND ACCEPTED:
  

VASCULAR BIOGENICS
	 		 	BIOCLINICA
					
	By:	 	/s/ Amos Ron	 		 	By:	 	/s/ Ted Kaminer
					
	Print:	 	Amos Ron	 		 	Print:	 	Ted Kaminer
					
	Title:	 	CFO	 		 	Title:	 	Executive VP & CFO
					
	Date:	 	December 31, 2012	 		 	Date:	 	02-Jan-2013

  
 

 
 7 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

  
 

 
 Vascular Biogenics Ltd. 

Additional Medical Imaging Core Laboratory Services in Support of 

a Study Entitled: “A Randomized, Double-Blind, 12-Week, Placebo- 

Controlled Study Followed by a 12-Week Phase Without Placebo to 

Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Mild to 

Moderate Ulcerative Colitis.” 

BioClinica Addendum #40801_2 

July 26, 2013 version one 

August 29, 2013 version two 
  

 

  

 Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a
confidential treatment request and are indicated by [***]. 

  

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

 TABLE OF CONTENTS 
  

					
	 1. SCOPE OF WORK
	  	 	2	  
		
	 1.1. ADDENDUM ASSUMPTIONS
	  	 	2	  
		
	 2. ADDENDUM PROJECT FEES AND EXPENSES
	  	 	3	  
		
	 2.1. ADDENDUM PROJECT FEES
	  	 	3	  
	 2.2. ADDENDUM EXPENSES
	  	 	4	  
	 2.3. BILLING POLICY
	  	 	5	  
		
	 3. TERMS AND CONDITIONS
	  	 	5	  

  
 

 
 1 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	1.	SCOPE OF WORK 

 Vascular Biogenics Ltd. (hereinafter referred to as “VASCULAR
BIOGENICS”) has requested that BioClinica, Inc. and subsidiaries (hereinafter referred to as “BIOCLINICA”) provide additional medical imaging core laboratory services in support of an Ulcerative Colitis study. 

This Addendum serves to document the additional services requested for this study beyond those contained within the following: 

 

	 	•	 	Agreement #40801 between BIOCLINICA and VASCULAR BIOGENICS, executed 24 September 2012 

  

	 	•	 	Addendum #40801_1 between BIOCLINICA and VASCULAR BIOGENICS, executed 02 January 2013 

This Addendum also serves to document the fees for the additional services. 

 

	1.1.	ADDENDUM ASSUMPTIONS 

 Presented below is an outline of the additional and modified
services requested by VASCULAR BIOGENICS for an Ulcerative Colitis study that are not included within the original agreement. 
  

	 	•	 	Timeline extension due to recruitment period being extended through December 2013 

  

	 	•	 	Additional forty (40) Screening timepoints to be received. BIOCLINICA assumes that a total of 160 Patients will be screened in order to achieve 110 Patients enrolled on the study. 160 Total Screening timepoints to
include the 120 Screening timepoints in the original contract plus 40 additional Screening timepoints. 

 Eligibility
Review: 
  

	 	•	 	Forty (40) additional Screening timepoints to be received 

  

	 	•	 	Screening timepoints will be re-read by a second reader for screening timepoints with a score of < 2, assuming 20% or eight (8) of the 40 additional timepoints and an additional 10% or 12 of the 120 screening
timepoints in the current contract will be re-read. 

 Primary Review: 

 

	 	•	 	Each screening timepoint will only be read once for eligibility review and then count as baseline in the primary review assuming the same pool of two (2) readers that are reading for eligibility are the same as the
primary review. Timepoints read by the third reader for eligibility will be re-read by reader one (1) or two (2) in the primary review, assuming 5% of timepoints (two (2) timepoints) will be re-read. 

[***] 

  
 

 
 2 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	2.	ADDENDUM PROJECT FEES AND EXPENSES 

  

	2.1.	ADDENDUM PROJECT FEES 

 The fees for services detailed within this Addendum are
summarized below. BIOCLINICA will only charge pro-rata for work performed at the rates quoted. 
 As per the original agreement, BIOCLINICA
fees will increase annually beginning with month 25 of the project as defined by the actual (original) project start date. This increase will be equivalent to the percent increase in the Euro Harmonized Index of Consumer Prices (HICP). 

 

	2.1.1.	[***] 

  

	2.1.2.	[***] 

  
 

 
 3 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	2.2.	[***] 

  

	2.2.1.	[***] 

  

	2.2.2.	[***] 

  

	2.2.3.	[***] 

  
 

 
 4 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Vascular Biogenics Ltd. 

Ulcerative Colitis Study 
  

	2.2.4.	[***] 

  

	2.3.	BILLING POLICY 

 The above mentioned fees will continue to be billed to VASCULAR
BIOGENICS on a monthly basis and will include relevant back-up documentation. 
  

	3.	TERMS AND CONDITIONS 

 All services will be performed by BIOCLINICA as an Addendum to
BIOCLINICA Agreement #40801, and all terms and conditions of Agreement #40801 shall apply. 
 AGREED AND ACCEPTED: 

 

									
	VASCULAR BIOGENICS	 		 	BIOCLINICA
					
	By:	 	/s/ Amos Ron	 		 	By:	 	/s/ Ted Kaminer
					
	Print:	 	Amos Ron	 		 	Print:	 	Ted Kaminer
					
	Title:	 	CFO	 		 	Title:	 	Executive VP & CFO
					
	Date:	 	 November 4, 2013
	 		 	Date:	 	17 Oct 2013

  
 

 
 5 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]